Designer Genes: Scribe Therapeutics' CEO Benjamin Oakes is building a platform for customized Crispr therapeutics.
with a stunning 94% of patients treated hitting the desired outcomes. The FDA is expected to make a decision on approval before the end of the year. Other Crispr-derived therapeutics for type one diabetes and multiple types of cancer are in the pipeline.
There’s a lot of activity in the Crispr startup market. According to Pitchbook, some $3.3 billion in venture capital has flowed into the space since 2019. That’s a figure that doesn’t even account for the over half-dozen Crispr companies that have exited to public markets in the past few years, or the hundreds of millions flowing in from big pharma.
“The group that has gone and built Scribe is really the next-generation team out of the Doudna Lab,” says Greg Yap, a partner at Menlo Ventures. He acknowledges the company has a long way to go before it brings products to market but says its partnerships with big pharma are an early validation of the tech’s promise.
The company emerged from stealth in October 2020, simultaneously announcing it had signed a drug development agreement with Biogen with a $15 million upfront payment and potentially worth up to $400 million if certain development milestones were met. The agreement also entitles Scribe to royalties from any approved drug that results.
Despite the big dollars it’s potentially seeing with these deals, the company is being selective in its partnerships, says chief business officer Svetlana Lucas.“I’ve seen companies that partnered a ton,” she says. “Which looks amazing at the time but then very impossible to execute on in the long-term.” The risk, she says, is losing focus and stretching resources too thin to execute on multiple programs at once.
This approach, says Oakes, is easier to scale without running into manufacturing bottlenecks that can plague other biological therapies — see how quickly the Covid vaccines were scaled up. That’s in part because the nanoparticles are much simpler to build than other gene therapy methods, which often rely on building complicated molecules like custom viruses to get medicines to the right place in the body.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make BillionsBenjamin Oakes' Scribe Therapeutics is developing specialized Crispr proteins to tackle a wide range of diseases–and it’s garnered deals with Big Pharma potentially worth over $4 billion.
Baca lebih lajut »
This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make BillionsBenjamin Oakes' Scribe Therapeutics is developing specialized Crispr proteins to tackle a wide range of diseases–and it’s garnered deals with Big Pharma potentially worth over $4 billion.
Baca lebih lajut »
This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make BillionsBenjamin Oakes' Scribe Therapeutics is developing specialized Crispr proteins to tackle a wide range of diseases–and it’s garnered deals with Big Pharma potentially worth over $4 billion.
Baca lebih lajut »
San Diego biotech Heron Therapeutics cuts 25% of workers, second corporate restructuring in a yearThe biotechnology company — which makes cancer and pain-management therapies — has not reached profitability and its new management is taking actions to reserve cash
Baca lebih lajut »
Israel Passes Law Cementing Itself As Exclusive Nation-State Of Benjamin NetanyahuJERUSALEM—In what is being regarded internationally as a powerful declaration of national purpose, Israel passed a binding resolution Thursday cementing itself as the exclusive nation-state of Benjamin Netanyahu. “Israel was created by and for Benjamin Netanyahu, and as a homeland for the Netanyahuan people,” said…
Baca lebih lajut »
Bank of Canada should stop hiking interest rates now: Benjamin TalCIBC\u0027s Benjamin Tal talks about why he thinks the Bank of Canada has started overshooting with interest rate hikes. Watch here.
Baca lebih lajut »